New Nordic Healthbrands AB Logo

New Nordic Healthbrands AB

Develops and markets herbal supplements & beauty products for natural wellness consumers globally.

NNH | ST

Overview

Corporate Details

ISIN(s):
SE0001838038
LEI:
213800JGTLNSKRD49G44
Country:
Sweden
Address:
SÖDRA FÖRSTADSGATAN 3, 211 43 MALMÖ
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

New Nordic Healthbrands AB is a company specializing in the development, marketing, and sale of herbal-based dietary supplements, natural remedies, and beauty products. Since its establishment in 1990, the company has focused on leveraging its expertise in medicinal plants to create innovative products that address specific health and beauty needs. New Nordic emphasizes scientific validation and quality control, analyzing all ingredients in controlled laboratories to ensure the safety and effectiveness of its offerings. The company markets its distinct brands globally to consumers seeking natural wellness solutions.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all New Nordic Healthbrands AB filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for New Nordic Healthbrands AB

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for New Nordic Healthbrands AB via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2025-05-16 Karl Kristian Bergman Jensen Other Sell 5,000 115,000.00 SEK
2025-03-12 Karl Kristian Bergman Jensen Other Sell 5,000 74,900.00 SEK
2025-03-11 Karl Kristian Bergman Jensen Other Sell 5,000 79,500.00 SEK
2025-03-05 Karl Kristian Bergman Jensen Other Sell 5,000 81,250.00 SEK
2025-01-22 Karl Kristian Bergman Jensen Other Sell 5,000 73,300.00 SEK
2025-01-21 Karl Kristian Bergman Jensen Other Sell 5,000 73,500.00 SEK
2025-01-20 Karl Kristian Bergman Jensen Other Sell 5,000 73,500.00 SEK
2024-12-27 Karl Kristian Bergman Jensen Other Sell 5,000 74,050.00 SEK
2024-12-18 Karl Kristian Bergman Jensen Other Sell 5,000 73,300.00 SEK
2024-09-06 Karl Kristian Bergman Jensen Other Sell 4,000 61,960.00 SEK

Peer Companies

Clinical-stage biopharma developing oral therapies for neuropsychiatric diseases like schizophrenia.
United States of America
LBRX
L&C BIO Co., Ltd Logo
Develops tissue grafts, medical devices, and cosmetics for tissue regeneration medicine.
South Korea
290650
LEAP THERAPEUTICS, INC. Logo
Clinical-stage biopharma developing targeted immuno-oncology antibody therapies for cancer.
United States of America
LPTX
Legend Biotech Corp Logo
Develops and commercializes CAR-T cell therapies for cancer, including CARVYKTI® for myeloma.
United States of America
LEGN
LENZ Therapeutics, Inc. Logo
Develops a prescription eye drop for presbyopia, the age-related loss of near vision.
United States of America
LENZ
Lexeo Therapeutics, Inc. Logo
Develops AAV gene therapies for genetic cardiovascular and Alzheimer's diseases.
United States of America
LXEO
LEXICON PHARMACEUTICALS, INC. Logo
Develops gene-based drugs for chronic diseases, including treatments for heart failure.
United States of America
LXRX
Lidds AB Logo
Develops oncology drugs using a technology for local, controlled, and sustained drug release.
Sweden
LIDDS
LIFECORE BIOMEDICAL, INC. \DE\ Logo
A CDMO for parenteral drugs, producing injectable-grade sodium hyaluronate (HA).
United States of America
LFCR
Liminatus Pharma, Inc. Logo
Clinical-stage immuno-oncology firm developing cancer therapies targeting the CD47 checkpoint.
United States of America
LIMN

Talk to a Data Expert

Have a question? We'll get back to you promptly.